What Is Simple Hyperplasia of the Uterine Lining?

Simple hyperplasia is a benign overgrowth of the uterine lining driven by prolonged estrogen exposure without adequate progesterone to balance it. In practical terms, the endometrium thickens more than it should because both its glandular and stromal components keep proliferating, producing what pathologists describe as an exaggerated version of the normal proliferative phase of the menstrual cycle. It is the most common form of endometrial hyperplasia and carries a low risk of progressing to cancer, but it does need monitoring and often treatment to resolve.

What Happens Inside the Uterine Lining

Every menstrual cycle, estrogen stimulates the endometrium to grow during the first half, and then progesterone steps in after ovulation to mature and stabilize that growth. When ovulation doesn’t happen, or when estrogen comes from another source without progesterone to counteract it, the lining just keeps thickening. Simple hyperplasia is essentially the result of that unchecked growth signal persisting over time.¹

What makes simple hyperplasia “simple” is that the glands and the surrounding stroma both grow together in proportion. The normal ratio between glandular tissue and stromal tissue stays roughly intact, and the glands don’t crowd against each other or take on irregular shapes.² The cells themselves look essentially normal, though they may be slightly larger than usual. This balanced pattern is what separates it from complex hyperplasia, where glandular architecture becomes irregular and crowded, and from atypical hyperplasia, where the cells themselves start to look abnormal under the microscope.

Who Gets It and Why

The common thread in almost every risk factor for simple hyperplasia is estrogen acting on the endometrium without progesterone to keep it in check. During the reproductive years, conditions that interfere with regular ovulation are the main culprit. Polycystic ovary syndrome is the most familiar example: irregular or absent ovulation means the endometrium gets months of estrogen stimulation with little or no progesterone to counterbalance it. Around perimenopause, ovulation becomes increasingly erratic, and strings of anovulatory cycles are common, which is why simple hyperplasia peaks in that age group.

After menopause, the risk shifts to factors that raise circulating estrogen levels. Obesity is a major one because fat tissue converts androgens into estrogen. Estrogen-only hormone replacement therapy, without a progestin, is another well-known driver. Certain medications can also tip the balance. Tamoxifen, widely used in estrogen-receptor-positive breast cancer, acts as an estrogen agonist on the uterine lining even though it blocks estrogen in breast tissue. Studies consistently show that tamoxifen users have significantly thicker endometrial linings and higher rates of hyperplasia than non-users. One comparative study found hyperplasia in about 28% of tamoxifen users versus 10% of non-users.³ Broader estimates put the incidence of endometrial hyperplasia in tamoxifen-treated postmenopausal women at roughly 1% to 20%, compared with 0% to 10% in those not taking the drug.⁴

Symptoms and How It Gets Caught

The hallmark symptom is abnormal uterine bleeding. That can mean heavier-than-usual periods, bleeding between periods, or any bleeding after menopause.⁵ There are no symptoms unique to simple hyperplasia versus other types, so the bleeding itself doesn’t tell you which kind you have. What it does tell you is that something in the uterine lining needs investigation. Roughly 10% to 20% of postmenopausal bleeding will turn out to be either hyperplasia or cancer, which is why clinicians treat any unexpected bleeding as a reason to look further.⁶

The first step in evaluation is usually a transvaginal ultrasound, which measures how thick the endometrial lining is. At a threshold of 5 mm, ultrasound picks up about 90% of endometrial abnormalities, though its positive predictive value for any abnormality is low, around 9%.⁷ In other words, ultrasound is good at ruling out a problem when the lining is thin, but a thick lining doesn’t necessarily mean hyperplasia. That’s why a tissue sample, obtained through an endometrial biopsy or curettage, is needed for a definitive diagnosis. Only a pathologist looking at the actual tissue under a microscope can confirm whether the overgrowth is simple hyperplasia, complex, atypical, or something else entirely.

How Classification Has Changed

If you’ve read about endometrial hyperplasia and found the terminology confusing, you’re not alone. The classification system has undergone significant revision. The older World Health Organization system from 1994 split hyperplasia into four categories based on two features: whether the glandular architecture was simple or complex, and whether the cells showed nuclear atypia. That gave you simple hyperplasia, complex hyperplasia, simple atypical hyperplasia, and complex atypical hyperplasia.⁸

The updated 2014 WHO classification, now widely adopted, simplified things into just two groups: hyperplasia without atypia (sometimes called benign hyperplasia) and atypical hyperplasia, also known as endometrial intraepithelial neoplasia or EIN. Under this newer system, “simple hyperplasia” falls into the hyperplasia-without-atypia bucket. The reason for the change is that the distinction that matters most clinically is the presence or absence of atypia, because atypia is the feature most strongly linked to cancer progression. Whether the architecture is simple or complex matters less for predicting outcomes than whether the cells themselves look abnormal.

The two systems don’t map onto each other neatly. A systematic review looking at how well the 1994 categories translated into the newer EIN system found only fair agreement for non-atypical hyperplasia overall, with simple non-atypical hyperplasia showing very high agreement with a benign EIN classification.⁹ In practice, this means if your pathology report uses the older terminology and says “simple hyperplasia without atypia,” it aligns well with the newer system’s benign hyperplasia category. If it says “complex hyperplasia without atypia,” the translation is murkier. The older term “simple hyperplasia” is still commonly used in clinical conversation and pathology reports, though the formal nomenclature has moved on.

Cancer Risk With Simple Hyperplasia

This is usually the question that worries people most, and the answer is reassuring. Simple hyperplasia without atypia carries a very low risk of progressing to endometrial cancer. One study tracking the natural history of endometrial hyperplasia found that 79% of simple hyperplasia cases regressed on their own without treatment.¹⁰ A systematic review and meta-analysis estimated that among women with non-atypical hyperplasia (which includes simple hyperplasia), progression to cancer occurred at a rate of about 2.6% per year.¹¹ That per-year figure sounds more alarming than it actually is: the overwhelming majority of these cases regress with treatment or even spontaneously, so cumulative lifetime risk stays low.

Compare that to atypical hyperplasia, where the estimated risk of progression to endometrial cancer is 8% to 29%, and the difference in clinical urgency becomes clear.¹² In tamoxifen-associated hyperplasia specifically, the prognosis also tracks with atypia: patients with atypical hyperplasia progress to carcinoma about 23% of the time, while those without atypia progress only about 2% of the time.¹³ The underlying message is consistent: atypia is the real red flag. Simple hyperplasia without it is a condition to manage, not a cause for panic.

Treatment Options

Since the root cause of simple hyperplasia is estrogen without adequate progesterone, the first-line treatment is to restore that hormonal balance. The two main approaches are oral progestin medications and a levonorgestrel-releasing intrauterine device (commonly known by brand names like Mirena). Both work, but the IUD consistently outperforms pills in head-to-head comparisons.

A meta-analysis found that for simple hyperplasia specifically, oral progestins achieved a regression rate of about 89%, while the levonorgestrel IUD achieved roughly 96%. That gap was not statistically significant for simple hyperplasia alone, but the advantage of the IUD became much more pronounced for complex and atypical types.¹⁴ Another meta-analysis of randomized trials found that the IUD achieved significantly higher therapeutic response rates than oral progestins at every time point measured, from three months out to two years, and also led to fewer hysterectomies.¹⁵

A separate large study reported a regression rate of 93% with the IUD compared to 66% with oral progestins, with both groups showing a median follow-up of about 10 months.¹⁶ The practical advantages of the IUD extend beyond efficacy: it delivers progesterone directly to the uterine lining, which means fewer systemic side effects like mood changes, bloating, or weight gain that oral progestins can cause. It also doesn’t depend on remembering to take a daily pill, which matters over months of treatment.

Whichever method is chosen, follow-up biopsies are standard to confirm that the lining has returned to normal. Treatment typically continues for at least six months, and some guidelines recommend keeping the IUD in place for longer to prevent recurrence, especially if the underlying risk factors haven’t changed.

The Role of Weight Loss and Metformin

Because obesity is a major driver of excess estrogen, weight loss has long been a logical adjunct to hormonal treatment for endometrial hyperplasia. The evidence is still thin, but what exists is encouraging. A systematic review looking at women who had bariatric surgery found that among those with hyperplasia before surgery, about 71% had complete resolution of the condition after weight loss, though the review noted the data quality was too poor to draw firm conclusions.¹⁷

A more recent study found that patients who lost more than 3% of their body weight had a disease reversal rate of about 91% compared with roughly 78% among those who didn’t lose that much. Metformin, the diabetes drug, showed an even stronger independent association with reversal: about 93% of metformin users had their hyperplasia resolve versus 52% of non-users.¹⁸ Metformin likely works by improving insulin sensitivity and lowering circulating insulin levels, which in turn reduces ovarian androgen production and the subsequent conversion of androgens to estrogen. These findings are promising, but both weight loss and metformin are studied as additions to progestin therapy, not replacements for it.

When Surgery Is Considered

For simple hyperplasia without atypia, surgery is rarely the first option. The standard approach is medical treatment with progestins, and hysterectomy typically comes into play only when the condition doesn’t respond to medical therapy, when the bleeding remains unmanageable, or when a patient prefers a definitive solution and has no plans for future pregnancy. There is broad clinical consensus that observation and medical treatment are the first-line strategies, with total hysterectomy reserved as a second-line option in specific cases.¹⁹

The calculus changes if follow-up biopsies show progression to atypical hyperplasia, which happens in a small minority of cases. Atypical hyperplasia is treated more aggressively because of its higher cancer risk, and hysterectomy is often recommended upfront for postmenopausal women or those who have completed childbearing. For younger women who want to preserve fertility, even atypical hyperplasia can sometimes be managed medically under close surveillance, though this requires a highly individualized approach with frequent biopsies.

What Cellular Studies Reveal About These Lesions

Researchers have looked closely at what’s happening at the cellular level in simple hyperplasia to understand why it behaves so differently from atypical hyperplasia. One key finding is that the cell proliferation rate in simple hyperplasia is actually lower than in normal proliferative endometrium, not higher. A study measuring Ki-67 (a marker of how actively cells are dividing) found an index of about 16% in simple hyperplasia versus 38% in basic proliferative endometrium.²⁰ That sounds counterintuitive for a condition defined by overgrowth, but it makes sense when you consider the other side of the equation: cell death. The ratio of programmed cell death (apoptosis) to proliferation was highest in simple hyperplasia, meaning the cells were dying off less efficiently relative to how slowly they were growing. The tissue builds up not because cells are dividing wildly, but because the normal process of shedding and turnover has slowed down.

Importantly, simple hyperplasia does not show the genetic markers associated with cancer. The same study found no expression of p53 or c-erbB-2, two proteins linked to malignant transformation, in either basic endometrium or hyperplasia without atypia. Atypical hyperplasia, by contrast, shares many of the same mutated genes found in endometrial carcinoma, including PTEN, PIK3CA, and KRAS.²¹ This molecular gap is why atypical hyperplasia is now classified alongside early neoplasia in the updated WHO system, while simple hyperplasia sits firmly in the benign category.

Hyperplasia Beyond the Uterus

The term “simple hyperplasia” sometimes causes confusion because hyperplasia as a concept isn’t limited to the endometrium. In its broadest sense, hyperplasia refers to any increase in the size of a tissue or organ due to an increase in the number of its cells. It occurs throughout the body in response to chronic stimulation. Thyroid tissue can undergo hyperplasia in response to excessive thyroid-stimulating hormone. The adrenal glands can enlarge in response to chronic ACTH stimulation. Prostate tissue hyperplasia (BPH) is extremely common in aging men. In endocrine organs, this kind of growth is generally considered reversible if the stimulus is removed, which distinguishes it from true neoplasia.²²

Endometrial simple hyperplasia fits this broader pattern perfectly. It is a tissue responding to a chronic hormonal signal (estrogen), growing in a measured and proportionate way, and regressing when the stimulus is counteracted by progesterone or removed entirely. The reason clinicians take it seriously despite its benign nature is the anatomical context: the uterine lining is a tissue that, under the right conditions, can undergo malignant transformation. Monitoring and treating even the benign form is a way of keeping those conditions from accumulating over years, especially in women with ongoing risk factors they can’t easily change.